The Decibel Skinny, Inc. Part 1: the Canadian connection to Ozempic
26 snips
Feb 23, 2026 
Kelly Grant, veteran health reporter, breaks down rising obesity trends and patient stories around GLP-1 drugs. Dr. Daniel Drucker, pioneering endocrinologist, walks through decades of research from a Gila monster discovery to semaglutide’s development. They discuss how these medicines work, broader health effects beyond weight, treatment challenges, and why the drugs captured public attention.
AI Snips
Chapters
Transcript
Episode notes
GLP-1s Affect Many Risk Factors
- GLP-1s do more than lower weight and blood sugar; they modify multiple cardiovascular and metabolic risk factors.
- Daniel Drucker notes effects include lowering blood pressure, inflammation, blood fats and influencing coagulation.
Brain Action Drives GLP-1 Weight Loss
- Weight loss from GLP-1s is mediated primarily through the brain, not peripheral gut action.
- Drucker cites mouse experiments where removing brain GLP-1 receptors abolishes weight loss and GI effects like slowed gastric emptying.
Obesity Rates Rising In Canada
- Canadian obesity rates have risen: 68% of adults are overweight or obese and 33% meet obesity criteria, up from pre-pandemic levels.
- Kelly Grant cites Statistics Canada physical-measure surveys and rising prevalence since before COVID-19.